– CANADA, Toronto – POINT Biopharma Inc., a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced the appointments of Jonathan Goodman, Gerry Hogue, and Peggy Gilmour to its Board of Directors.
“I am very pleased to welcome these highly qualified individuals to POINT’s Board of Directors,” said Executive Chairman, Allan Silber. “Their significant experience in pharmaceuticals, oncology, regulatory and audit will further accelerate POINT’s success.”
About Jonathan Goodman
Mr. Goodman was the co-founder, President, and CEO of publicly-traded Paladin Labs Inc (TSE: PLB), which was acquired in 2014 by Endo International Inc. (NASDAQ: ENDP) for $3.2 billion. The same day that Paladin was sold, Mr. Goodman started a second publicly-traded specialty pharmaceutical company, Knight Therapeutics Inc. (TSE: GUD). Mr. Goodman is a recipient of the Globe and Mail’s Top 40 Under 40 award, Federation CJA’s Sam Steinberg Award for entrepreneurial excellence and Koach Award for leading campaigner, UIA Federations of Canada National Young Leadership Award of Distinction, the Special Recognition Award by Brain Injury Canada, Bernard Gross Leadership Award by ORT Montreal, was appointed Honorary Chairman of the Ride to Conquer Cancer and was named Quebec Entrepreneur of the Year in the Life Sciences by the National Post and Ernst & Young.
About Gerry Hogue
Gerry Hogue is the founder of VieCure, an oncology EMR software platform, and presently serves as its President & CEO. Mr. Hogue has spent many years working in the field of enabling technologies for cancer care. In 1993, Mr. Hogue founded OpTx Corporation, which created the world’s first oncology-specific electronic medical record and decision support system.
About Peggy Gilmour
Peggy Gilmour is a senior finance, risk management, and audit executive with a deep understanding of both US and Canadian regulatory environments. Most recently, Ms. Gilmour was Board Chair of the Institute of Internal Auditors, Toronto Chapter, and has previously held board, audit, governance & risk roles with organizations such as Metrolinx, Interac, and Ontario Pension Board. A chartered accountant by training, Ms. Gilmour gained her extensive finance experience as CFO of the Operations & Technology Division within BMO Financial Group and as SVP of Finance at Aviva Insurance Canada.
About POINT Biopharma
POINT Biopharma is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is combining a portfolio of best in class radiopharmaceutical assets, a seasoned management team, strategic partnerships in radio-isotope supply, manufacturing technology, and novel direct to patient targeting to revolutionize theranostic drug development and radioligand commercialization.
For more information: https://www.pointbiopharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.